OptiBiotix Health has recently signed distribution deals for its CholBiome supplements in the ASEAN region which include Singapore, Philippines, Thailand, Indonesia as well as India and Australia.
These supplements will be sold at pharmacies and hospitals to fight the rising number of cardiovascular diseases in this region, attributed to high blood pressure and high cholesterol.
The CholBiome supplements contain patented probiotic strain Lactobacillus plantarum (branded LPLDL) to manage cardiovascular risk factors.
In Singapore, OptiBiotix had signed distribution deal with United Italian Trading Corporation (UITC), while it is signing up with Actial Farmaceutica, producer of the VSL 3 range of probiotic, to distribute its CholBiome supplements into Australia, Indonesia and Thailand. In the Philippines, CholBiome will be distributed by CTC Far East Philippines.
CholBiome probiotic strain, LPLDL has been clinically backed for its efficacy, and further research are underway to evaluate its other health benefits like improving sleep, and reducing stress.